Baseline carcinoembryonic antigen (CEA) as a predictive factor of ramucirumab efficacy in RAISE, a second-line metastatic colorectal carcinoma (mCR...

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter T. Yoshino
Citation Annals of Oncology (2016) 27 (2): 102-117. 10.1093/annonc/mdw200
Authors T. Yoshino1, R. Obermannová2, G. Bodoky3, R. Garcia-Carbonero4, T.-. Ciuleanu5, D. Portnoy6, W. Kim Tae7, Y. Hsu8, L. Yang8, D. Ferry8, F. Nasroulah9, J. Tabernero10
  • 1National Cancer Center Hospital East, Kashiwa, Japan, /
  • 2Klinika Komplexní Onkologické Pécˇe a Lékarˇská Fakulta Masarykovy Univerzity v Brneˇ, Brno, Czech Republic, /
  • 3Szent László Hospital, Budapest, Hungary, /
  • 4Hospital Universitario 12 de Octubre, Madrid, Spain, /
  • 5Prof. Dr. I. Chiricuta Institute of Oncology, Napoca, Romania, /
  • 6West Clinic, Memphis, Tennessee, USA, /
  • 7Asan Medical Center, University of Ulsan College of Medicine, Songpa-gu, Republic of Korea, /
  • 8Eli Lilly and Company, Bridgewater, New Jersey, USA, /
  • 9Eli Lilly and Company, Buenos Aires, Argentina, /
  • 10Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology, Barcelona, Spain, /

Abstract

Ramucirumab is a human IgG1 monoclonal antibody that targets the vascular endothelial growth factor receptor-2. The RAISE phase 3 clinical trial demonstrated ramucirumab + FOLFIRI significantly improved overall survival (OS) (hazard ratio [HR] = 0.84, 95% CI: 0.73–0.98, p = 0.022) and progression-free survival (PFS) (HR = 0.79, 95% CI: 0.70–0.90, p = 0.0005) compared to placebo + FOLFIRI for second-line mCRC patients previously treated with first-line bevacizumab, oxaliplatin, and a fluoropyrimidine. Elevated baseline serum CEA levels are a negative prognostic factor for mCRC and inversely correlate with OS/PFS in first-line bevacizumab-based treatment (Prager et al, Cancer Sci 2014;105:996-1001). CEA has been shown to enhance tumor cell survival and induce tumor angiogenesis in vitro by activating integrin pathways. We undertook post-hoc analyses of RAISE patient data to examine association of CEA subgroups with efficacy parameters.